1. Home
  2. KRNY vs VSTM Comparison

KRNY vs VSTM Comparison

Compare KRNY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

N/A

Current Price

$7.31

Market Cap

466.6M

Sector

Finance

ML Signal

N/A

Logo Verastem Inc.

VSTM

Verastem Inc.

N/A

Current Price

$5.84

Market Cap

470.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRNY
VSTM
Founded
1884
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.6M
470.7M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
KRNY
VSTM
Price
$7.31
$5.84
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$8.00
$15.00
AVG Volume (30 Days)
265.2K
1.3M
Earning Date
04-22-2026
05-18-2026
Dividend Yield
5.99%
N/A
EPS Growth
130.22
17.49
EPS
0.30
N/A
Revenue
$2,580,000.00
$30,914,000.00
Revenue This Year
$3.89
$254.18
Revenue Next Year
$17.52
$99.39
P/E Ratio
$24.47
N/A
Revenue Growth
36.00
209.14
52 Week Low
$5.45
$4.01
52 Week High
$8.50
$11.25

Technical Indicators

Market Signals
Indicator
KRNY
VSTM
Relative Strength Index (RSI) 35.20 43.52
Support Level $6.30 $5.56
Resistance Level $8.42 $6.91
Average True Range (ATR) 0.26 0.33
MACD -0.07 0.08
Stochastic Oscillator 12.94 31.86

Price Performance

Historical Comparison
KRNY
VSTM

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: